European CHMP recommends tagraxofusp (Elzonris) for treatment of blastic plasmacytoid dendritic cell neoplasm

Tagraxofusp is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive type of acute myeloid leukaemia.

Source:

European Medicines Agency